Bayer AG (Xetra: BAYN) has announced a series of new cardiovascular, kidney and stroke research presentations for the American Heart Association Scientific Sessions 2026, including an exploratory analysis from its pivotal OCEANIC-STROKE trial and additional studies of finerenone across chronic kidney disease and heart failure. Announced on November 3, 2026, the programme will be presented in Chicago from November 6 to 9 and comes shortly after Bayer secured China’s first marketing approval for an oral Factor XIa inhibitor.
The meeting will feature a late-breaking analysis examining asundexian’s effects across different baseline cardiovascular risk categories, alongside new research from the FINEARTS-HF, FINE-HEART and CONFIDENCE programmes. The presentations will examine how finerenone performs in patients with different kidney failure risks, heart failure characteristics and clinical profiles, including individuals receiving simultaneous treatment with the sodium-glucose cotransporter 2 inhibitor empagliflozin.
The clinical programme has growing commercial importance. Bayer reported third-quarter 2026 pharmaceutical sales of €4.68 billion, with Kerendia revenue expanding strongly as the company seeks to offset pressure on older medicines. However, the new AHA subgroup findings are largely scheduled rather than disclosed, and several statistical comparisons will be exploratory. Their significance will depend on whether they add reliable clinical information beyond results already established in the parent trials.
Why is the November 2026 AHA meeting particularly important for Bayer’s cardiovascular portfolio?
Bayer’s research programme addresses several interrelated conditions: recurrent stroke, chronic kidney disease and heart failure. These diseases frequently coexist, particularly among older adults and patients with diabetes or other cardiometabolic risk factors. Improving outcomes requires attention to blood clot formation, kidney function, cardiac performance and the effects of commonly used medicines.
Asundexian represents Bayer’s effort to develop a new approach to preventing recurrent ischaemic stroke. Its mechanism differs from conventional anticoagulants because it selectively inhibits activated Factor XI, a component of the coagulation pathway. The objective is to reduce harmful clot formation while limiting interference with haemostatic mechanisms needed to prevent excessive bleeding.
Finerenone addresses a different biological pathway. The medicine is a non-steroidal mineralocorticoid receptor antagonist that influences processes associated with inflammation, fibrosis and cardiovascular and kidney injury. Its development has expanded from chronic kidney disease associated with type 2 diabetes into heart failure and, more recently, chronic kidney disease associated with type 1 diabetes.
The November presentations provide an opportunity to examine how the benefits and risks of these medicines vary across patient subgroups. However, scientific value depends on whether the analyses are adequately supported by the data and whether their findings could influence clinical decisions. Exploratory statistical results should not automatically be treated as new treatment recommendations.
What did the Phase 3 OCEANIC-STROKE trial establish about asundexian’s effectiveness?
OCEANIC-STROKE enrolled 12,327 patients who had experienced a recent non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack. The randomised, double-blind trial compared once-daily asundexian 50 mg with placebo, with both groups receiving antiplatelet treatment. The objective was to determine whether additional Factor XIa inhibition could reduce recurrent ischaemic stroke without producing unacceptable bleeding.
The study demonstrated a statistically significant 26% relative reduction in recurrent ischaemic stroke. The reported hazard ratio was 0.74, with a 95% confidence interval of 0.65 to 0.84 and a p-value below 0.0001. These findings provide the principal efficacy evidence supporting the medicine’s regulatory development.
The absolute event rates are equally important. Approximately 6.2% of patients receiving asundexian experienced an ischaemic stroke, compared with 8.4% receiving placebo during the evaluated period. This represents an absolute difference of approximately 2.2 percentage points, illustrating the distinction between relative risk reduction and the proportion of patients directly experiencing the outcome.
Bayer also reported no increase in International Society on Thrombosis and Haemostasis major bleeding compared with placebo. The finding is central to the development rationale because intensifying antithrombotic therapy can increase bleeding risk. However, it does not establish that asundexian carries no bleeding risk or that every patient can use it safely.
The trial provides strong evidence in its defined population, but the results should not be generalised automatically to cardioembolic stroke or atrial fibrillation. Different mechanisms of stroke require different prevention strategies, and regulatory indications must reflect the populations studied.
What will the new OCEANIC-STROKE Framingham risk analysis add to the evidence?
Bayer has scheduled a late-breaking presentation on November 7 examining outcomes according to categories derived from a non-laboratory Framingham cardiovascular risk score. The score uses clinical information to estimate cardiovascular risk without requiring the full set of laboratory measurements used by some other prediction tools. The analysis will investigate whether baseline risk influences outcomes observed with asundexian.
This is relevant because the absolute benefit of preventing recurrent stroke can vary according to a patient’s underlying probability of experiencing another event. A treatment producing a similar relative risk reduction across risk categories may have different absolute effects in lower-risk and higher-risk patients. Clinicians therefore need to understand both relative effectiveness and the underlying event rate.
However, the announced analysis is explicitly exploratory and post hoc. It examines subgroups after the parent trial’s main design and outcome assessment, creating a greater risk of chance findings and multiple-comparison problems. Any apparent difference between categories would require careful interpretation.
The November 3 announcement does not disclose the new subgroup hazard ratios, event rates or interaction statistics. Consequently, the presentation should not be described as establishing that asundexian works better in one Framingham risk category than another. Those conclusions depend on results still scheduled for presentation.
A useful finding would clarify whether the treatment effect remains consistent across clinically relevant risk profiles. A more consequential claim involving differential benefit would require robust evidence and appropriate statistical support.
Why is China’s October 2026 approval of asundexian a major regulatory milestone?
On October 26, 2026, China’s National Medical Products Administration approved asundexian under the brand name Sunharbo. The 50 mg once-daily treatment is authorised to reduce the risk of stroke in adults following a non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack. Bayer described it as the first Factor XIa inhibitor to receive marketing authorisation in China.
The approval represents an important transition from clinical development into an authorised commercial market. It is supported by the positive OCEANIC-STROKE results and follows priority review by the Chinese regulator. However, Bayer has not disclosed complete information about the medicine’s Chinese launch timetable, pricing or expected sales contribution.
As of November 3, asundexian remained under regulatory review in the United States, European Union and Japan. These reviews are separate processes, and the Chinese approval does not guarantee a favourable decision elsewhere. Each regulator must assess the complete efficacy, safety and manufacturing evidence under its applicable standards.
The commercial opportunity is substantial because China has a large population affected by ischaemic stroke. However, potential sales cannot be estimated simply from the disease burden. Actual use will depend on the authorised population, reimbursement, physician adoption and the medicine’s positioning alongside existing preventive treatments.
Asundexian could eventually contribute to Bayer’s effort to replace revenue lost from older medicines facing generic competition. Nevertheless, its contribution remains uncertain until regulatory access and commercial uptake become clearer.
How do the earlier stroke severity findings support Bayer’s clinical argument for asundexian?
In May 2026, Bayer presented additional OCEANIC-STROKE analyses examining the severity of recurrent strokes and associated disability. Among participants who experienced a subsequent ischaemic stroke, the proportion with a National Institutes of Health Stroke Scale score of at least eight was lower in the asundexian group than in the placebo group. The reported proportions were 22.9% and 30.3%, respectively.
The company also reported fewer disabling strokes in the asundexian group. Such events occurred in approximately 2.1% of patients receiving the investigational medicine and 3.0% receiving placebo, with a reported cause-specific hazard ratio of 0.69. These findings suggest that the potential benefits may extend beyond reducing the overall number of recurrent strokes.
However, the interpretation of severity analyses requires care. Comparing characteristics only among patients who experienced a stroke can be affected by the treatment’s influence on who experiences an event. Such analyses should not be treated as definitive evidence of a separate biological effect on stroke severity without considering the statistical design.
Preventing disabling strokes is clinically important because the consequences can include long-term loss of independence, impaired mobility and substantial care requirements. A treatment that reduces such events could have meaningful effects on patients and healthcare systems. The strength of that conclusion nevertheless depends on the complete clinical evidence.
The forthcoming Framingham risk analysis may add another perspective by investigating baseline patient characteristics rather than stroke severity alone. It remains important to distinguish already disclosed results from the new AHA findings.
What does finerenone’s expanding US approval status mean for Kerendia?
Kerendia, containing finerenone, has received US FDA approvals covering several cardiovascular and kidney disease populations. It is authorised to reduce specified kidney and cardiovascular risks in adults with chronic kidney disease associated with type 2 diabetes. It is also approved to reduce cardiovascular death, heart failure hospitalisation and urgent heart failure visits in adults with heart failure and left ventricular ejection fraction of at least 40%.
In September 2026, the FDA authorised an additional indication involving adults with chronic kidney disease associated with type 1 diabetes. The approval covers reduction of urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustained kidney function decline and end-stage kidney disease. This is a narrower claim than an indication based on direct demonstration of fewer kidney failure events.
The type 1 diabetes approval followed the FINE-ONE programme, which demonstrated a statistically significant reduction in urinary albumin-to-creatinine ratio. Bayer reported a 25% treatment difference compared with placebo over six months when finerenone was added to standard care. These results supported the regulatory decision within the relevant evidence framework.
The expanding indications increase the range of patients who may be considered for treatment, but they do not make finerenone suitable for everyone with kidney disease or heart failure. Kidney function, potassium levels and concurrent medicines are important in determining appropriateness. The prescribing requirements differ according to the indication and dose.
Kerendia’s commercial expansion therefore depends on appropriate patient identification and adherence to safety monitoring. Its new AHA analyses may provide additional information relevant to these decisions.
Why is the FINEARTS-HF programme important for heart failure patients with preserved or mildly reduced ejection fraction?
Heart failure with preserved or mildly reduced ejection fraction represents a substantial treatment challenge because patients may experience serious symptoms and recurrent hospitalisation despite maintaining a relatively preserved proportion of blood ejected by the left ventricle. The disease can involve complex interactions among cardiac structure, kidney function, inflammation and metabolic conditions.
FINEARTS-HF evaluated finerenone in approximately 6,000 patients with symptomatic heart failure and left ventricular ejection fraction of at least 40%. The randomised trial demonstrated a statistically significant reduction in its primary composite endpoint of total worsening heart failure events and cardiovascular death. The reported rate ratio was 0.84, corresponding to a 16% relative reduction in the combined event rate.
The benefit was driven principally by fewer worsening heart failure events. Cardiovascular death alone did not show a statistically significant reduction, with a reported hazard ratio of 0.93. This distinction matters because the overall trial’s success should not be described as proof of a survival advantage.
At AHA 2026, Bayer will present additional analyses examining the kidney failure risk equation and outcomes across different patient risk profiles. Other presentations will investigate health status and sex-related differences in preserved-ejection-fraction heart failure. These findings could help identify characteristics relevant to treatment decisions.
However, the new subgroup results remain scheduled. They must be interpreted within the broader controlled evidence, and differences between subgroups should not be regarded as established unless supported by appropriate interaction analyses.
How does the CONFIDENCE trial support simultaneous finerenone and empagliflozin treatment?
CONFIDENCE was a Phase 2 clinical trial examining the simultaneous initiation of finerenone and empagliflozin in adults with chronic kidney disease associated with type 2 diabetes. Empagliflozin is a sodium-glucose cotransporter 2 inhibitor marketed under established brands by its commercial partners. The two medicines affect different biological pathways relevant to kidney protection.
The trial compared combination treatment with either medicine administered alone. At 180 days, the combination produced an approximately 52% reduction in urinary albumin-to-creatinine ratio from baseline. This represented a greater reduction than either individual treatment, with reported relative differences of 29% versus finerenone alone and 32% versus empagliflozin alone.
The study also found that approximately 70% of participants receiving the combination achieved a reduction in albuminuria greater than 30%, compared with approximately 52% in each monotherapy group. These results provide biological evidence supporting the use of complementary treatment mechanisms. However, albuminuria reduction is a surrogate measure rather than direct proof of fewer kidney failure events during the six-month trial.
Bayer will present new CONFIDENCE subgroup analyses at AHA on November 9. These will examine kidney failure risk, race and ethnicity, frailty, and baseline liver fibrosis risk. The objective is to understand whether the combination’s effects are consistent across clinically different populations.
The announcement does not disclose numerical findings from these new analyses. It would therefore be premature to claim superior outcomes within any individual subgroup. The established parent-trial results provide the foundation, while the forthcoming presentations may refine understanding of the treatment’s applicability.
Why does potassium monitoring remain a central safety consideration with finerenone?
Finerenone acts on mineralocorticoid receptor signalling, which has important roles in kidney and cardiovascular physiology. Inhibiting this pathway can provide benefits but may also increase serum potassium. Hyperkalaemia is therefore an established safety concern, particularly among patients with reduced kidney function.
The US prescribing information requires assessment of serum potassium and estimated glomerular filtration rate before treatment begins, followed by appropriate monitoring during therapy. Finerenone should not be initiated when potassium exceeds the specified threshold. Strong CYP3A4 inhibitors and certain other clinical conditions also affect treatment suitability.
The CONFIDENCE programme provides an opportunity to examine whether simultaneous administration with an SGLT2 inhibitor influences treatment tolerability. However, the presence of empagliflozin does not remove the need for potassium monitoring. The combination must be assessed using its observed safety profile.
The new AHA analyses include research concerning potassium levels and cardiovascular outcomes across cardio-kidney-metabolic disease. Such findings may improve understanding of risk factors and treatment management. Nevertheless, observational associations between potassium levels and outcomes do not automatically establish a safe alternative to established monitoring requirements.
For clinicians, the balance between kidney protection and hyperkalaemia risk remains central. Expanding indications increase the importance of selecting appropriate patients rather than applying one treatment strategy indiscriminately.
How do Bayer’s third-quarter 2026 results support the cardiovascular and kidney portfolio expansion?
Bayer reported third-quarter 2026 group sales of €10.053 billion, an increase of 4.1% on a reported basis. Earnings before interest, taxes, depreciation and amortisation before special items increased 6.9% to €1.615 billion. The Pharmaceuticals division was a central contributor, with sales increasing to €4.68 billion.
Growth was driven partly by strong performance from Nubeqa and Kerendia. Bayer reported that Kerendia’s sales increased approximately 64.9% on a currency- and portfolio-adjusted basis. The medicine’s revenue also exceeded €1 billion over the 12-month period ending September 2026, indicating a growing commercial contribution.
However, the group continued to face financial constraints. Its third-quarter net result was a loss of €672 million, reflecting factors including asset impairments and other charges. Free cash flow was negative €293 million, while net financial debt stood at approximately €31.083 billion at September 30.
Management improved selected full-year financial targets, including its adjusted operating earnings and free cash flow outlook. These developments suggest improving underlying performance, but the debt and cash flow position remain important considerations. The company must continue balancing investment in new medicines with financial obligations across its broader operations.
The cardiovascular and kidney portfolio offers growth opportunities as older pharmaceutical products face patent expiry and generic competition. However, new clinical presentations alone do not establish future revenue.
What does Bayer’s latest share performance reveal about investor sentiment?
Bayer shares closed at approximately €51.84 on Xetra on November 3, 2026, up 3.64% from the previous session’s close of €50.02. The shares had also advanced substantially during the preceding week, reflecting improving sentiment around the company’s operating performance and pipeline developments.
However, the increase should not be attributed exclusively to the AHA conference preview. Bayer released third-quarter financial results on the same date, including improved financial guidance. The recent Chinese approval of asundexian and expectations for growth across its pharmaceutical portfolio also form part of the broader investment context.
The company’s performance must be evaluated across pharmaceuticals, agricultural products and consumer health, rather than through one clinical programme alone. In particular, financial obligations and litigation-related risks can influence valuation independently of the medical evidence supporting individual products.
Kerendia’s commercial growth provides evidence that newer cardiovascular and kidney treatments are becoming more meaningful to Bayer’s revenue base. Asundexian could create an additional opportunity following China’s approval, but its potential sales contribution remains uncertain until market access and prescribing patterns develop.
Investor attention is therefore likely to focus on both regulatory execution and the sustainability of pharmaceutical growth. The AHA presentations may strengthen the clinical narrative, but their direct impact on earnings cannot yet be quantified.
What will determine whether Bayer’s AHA 2026 findings change clinical practice?
The most important requirement is that new analyses provide information capable of influencing patient selection or treatment decisions. Asundexian’s pivotal trial has already demonstrated a significant reduction in recurrent ischaemic stroke, but the forthcoming Framingham risk analysis may help clarify its performance across different baseline risk categories. Such subgroup findings must be supported by appropriate statistical interpretation.
For finerenone, the AHA programme will examine how existing trial results apply to different kidney and heart failure populations. Risk stratification may help clinicians understand where treatment provides meaningful benefit and which patients require additional safety precautions. However, exploratory analyses cannot independently establish new regulatory indications.
Long-term outcomes remain important. Improvements in albuminuria or cardiovascular risk markers can support biological plausibility, but patients and regulators also need evidence concerning clinical events such as kidney failure, heart failure hospitalisation and stroke. The meaning of each endpoint depends on the design of the study in which it was measured.
Bayer enters AHA Scientific Sessions 2026 with a substantially stronger cardiovascular portfolio than it had before the OCEANIC-STROKE results and recent regulatory approvals. Asundexian is now authorised in China, while Kerendia has expanded into additional US patient populations and is generating meaningful revenue growth.
The conference will provide another opportunity to refine the evidence supporting these medicines. However, their ultimate clinical and commercial significance will depend on robust outcomes, responsible safety management and successful implementation across the populations for which they are authorised.
